MUFG Securities EMEA plc Sells 35,477 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

MUFG Securities EMEA plc decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 58.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,870 shares of the company’s stock after selling 35,477 shares during the quarter. MUFG Securities EMEA plc’s holdings in IDEXX Laboratories were worth $4,626,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in IDXX. Pearl River Capital LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth $28,000. Sontag Advisory LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth $79,000. Quantamental Technologies LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth $92,000. Ipswich Investment Management Co. Inc. bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth $124,000. Finally, ETF Managers Group LLC increased its holdings in shares of IDEXX Laboratories by 15.8% in the 4th quarter. ETF Managers Group LLC now owns 682 shares of the company’s stock worth $127,000 after purchasing an additional 93 shares in the last quarter. Institutional investors and hedge funds own 88.24% of the company’s stock.

In other IDEXX Laboratories news, insider Michael Lane sold 971 shares of the business’s stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $208.00, for a total transaction of $201,968.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Lawrence D. Kingsley purchased 2,405 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were bought at an average cost of $208.68 per share, with a total value of $501,875.40. Following the acquisition, the director now directly owns 7,403 shares of the company’s stock, valued at approximately $1,544,858.04. The disclosure for this purchase can be found here. Insiders have sold 40,144 shares of company stock valued at $8,378,892 in the last three months. 2.70% of the stock is currently owned by corporate insiders.

Shares of IDXX traded up $0.13 during trading hours on Wednesday, hitting $224.58. The stock had a trading volume of 382,002 shares, compared to its average volume of 510,738. IDEXX Laboratories, Inc. has a 12 month low of $176.11 and a 12 month high of $256.22. The firm has a market capitalization of $19.09 billion, a P/E ratio of 52.72 and a beta of 0.97.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Friday, February 1st. The company reported $0.98 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.90 by $0.08. IDEXX Laboratories had a negative return on equity of 1,501.97% and a net margin of 17.03%. The company had revenue of $549.39 million during the quarter, compared to analyst estimates of $546.04 million. During the same quarter in the previous year, the company posted $0.43 earnings per share. IDEXX Laboratories’s revenue was up 8.5% compared to the same quarter last year. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 4.69 earnings per share for the current fiscal year.

A number of analysts have commented on the company. BidaskClub lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, April 11th. Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. Finally, Canaccord Genuity cut their price objective on IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating for the company in a report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $246.67.

COPYRIGHT VIOLATION WARNING: “MUFG Securities EMEA plc Sells 35,477 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)” was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/24/mufg-securities-emea-plc-sells-35477-shares-of-idexx-laboratories-inc-idxx.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: What is the NASDAQ?

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.